Thyrocare Technologies Limited (NSE:THYROCARE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Shareholders will be ecstatic, with their stake up 20% over the past week following Thyrocare Technologies Limited's (NSE:THYROCARE) latest quarterly results. It was a workmanlike result, with revenues of ₹1.6b coming in 2.1% ahead of expectations, and statutory earnings per share of ₹13.40, in line with analyst appraisals. The analyst typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analyst has changed their mind on Thyrocare Technologies after the latest results.

Check out our latest analysis for Thyrocare Technologies

Taking into account the latest results, the most recent consensus for Thyrocare Technologies from single analyst is for revenues of ₹6.50b in 2025. If met, it would imply a meaningful 9.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to jump 26% to ₹18.50. Before this earnings report, the analyst had been forecasting revenues of ₹6.50b and earnings per share (EPS) of ₹16.70 in 2025. There was no real change to the revenue estimates, but the analyst does seem more bullish on earnings, given the substantial gain in earnings per share expectations following these results.

The consensus price target was unchanged at ₹800, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analyst is definitely expecting Thyrocare Technologies' growth to accelerate, with the forecast 13% annualised growth to the end of 2025 ranking favourably alongside historical growth of 6.5% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 17% annually. So it's clear that despite the acceleration in growth, Thyrocare Technologies is expected to grow meaningfully slower than the industry average.

The Bottom Line

The most important thing here is that the analyst upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Thyrocare Technologies following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at ₹800, with the latest estimates not enough to have an impact on their price target.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for Thyrocare Technologies going out as far as 2026, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Thyrocare Technologies , and understanding it should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com